Forums

Forums

UHN Theranostics Forum, Full listing of Events

Date Speaker Talk 
21 Sep 2021

 

 Keith Stewart, MD

  • Vice President, Cancer
  • Director, Princess Margaret Cancer Program UHN
 Opening Remarks: The Importance and Vision of Theranostics at UHN
Ur Metser, MD

  • Site Director, Princess Margaret Cancer Centre
  • Division Head, Molecular Imaging
 Theranostics at UHN: Current Activity and Centre Vision
David Green, PhD

 Radiopharmaceuticals for Imaging and Therapy
19 Oct 2021

 

 Gang Zheng, PhD

  • Senior Scientist
  • Associate Research Director
  • Princess Margaret Cancer Centre, UHN

Michael Valic, PhD Candidate

  • Zheng lab, UHN
 Porphysome Nanotheranostics
Stephanie Lheureux, MD, PhD

  • Drug Development Program- Gynecology, Division of Medical Oncology & Hematology, Gynecology Site Lead
  • Princess Margaret Cancer Centre, UHN
 Porphysome Clinical Trial Design
16 Nov 2021

 

 Neil Fleshner, MD

  • Surgeon, Urology/Medical Director, BioSpecimen Services, UHN
  • Professor of Surgery and Chair, Division of Urology, Faculty of Medicine, UofT

Joe McCann, PhD

  • CEO, POINT Biopharma
 Radioligand Oncology Care:  Opportunities and Missed Opportunities
29 Mar 2022

 

 Bryan Bednarz, PhD

  • Medical Physics, University of Wisconsin
 The role of dosimetry and radiobiology in clinical radiopharmaceutical therapy
Reinier Hernandez, PhD

  • Assistant Professor of Medical Physics and Radiology
  • University of Wisconsin-Madison
 Expanding the efficacy of therapeutic radiopharmaceuticals
12 Apr 2022

 

 Katherine Vallis, MD

  • Professor of Experimental Radiotherapeutics, University of Oxford, UK
 Radionuclide Therapy: Some Radiobiological and Pharmacokinetic Considerations
Rebecca Wong, MD

  • Radiation Oncologist, Princess Margaret Cancer Centre, UHN
 Experience with individualized dosimetry at Princess Margaret
31 May 2022

 

 Jean-Mathieu Beauregard, MD, MSc, FRCPC

  • Associate Professor, Department of Radiology and Nuclear Medicine, Université Laval
  • Nuclear Medicine Physician, Department of Medical Imaging, CHU de Québec - Université Laval
  • Clinician-Scientist, Oncology Axis, CHU de Québec - Université Laval Research Center
 Optimizing dosimetry for personalized radiopharmaceutical therapy in real-world clinical practice
Brandon Driscoll M.A.Sc.

  • Techna, University Health Network

Ivan Yeung, PhD, FCCPM

  • Associate Head, Department of Medical Physics, Princess Margaret Cancer Centre,  UHN
  • Head, Department of Medical Physics, Stronach Regional Cancer Centre
 Improving personalized cancer medicine with individualized dosimetry for theranostics: lessons learned from a multi-site study.
20 Sep 2022

 

 Valerie Facca, PhD Candidate

  • Reilly Lab
  • Department of Pharmaceutical Sciences
  • Leslie Dan Faculty of Pharmacy, University of Toronto

Dave Cescon, MD, PhD

  • Medical Oncologist and Clinician Scientist
  • Princess Margaret Cancer Centre, UHN
 Evaluation of an EGFR-targeted theranostic for triple-negative breast cancer recurrence in metastatic and chemoresistant models
11 Oct 2022 Ken Herrmann, MD, MBA

  • Chair, Dept of Nuclear Medicine
  • Nuclear Medicine Physician and Clinician Scientist
  • Universitätsmedizin Essen, Germany
 FAP-Directed Imaging: What do we know so far?
29 Nov 2022

 

 Pallavi Jain, PhD

  • Medical Science Liaison, Prostate Cancer Therapeutics, AAA-Novartis

Loujin Houdaihed, PhD

  • Medical Science Liaison, NETs Therapeutics, AAA-Novartis
 Clinical Development program for radioligand therapy at AAA, A Novartis Company
18 Apr 2023

 

 Bruno Paquin, PhD

  • Chief Executive Officer, AtomVie Global Radiopharma
 The Ins and Outs of Radiopharmaceutical Manufacturing
16 May 2023

 

 Carlos Uribe, PhD, MCCPM

  • Clinical Nuclear Medicine Physics, BC Cancer;
  • Clinical Assistant Professor, UBC Radiology

Francois Bénard, MD

  • Senior Executive Director, Research, BC Cancer Research Institute
  • Professor, Department of Radiology, University of British Columbia
  • Associate Dean, Research, Faculty of Medicine, University of British Columbia
 Implementation of personalised radiopharmaceutical therapies; the BC Cancer experience

 

Development of radiopharmaceuticals for prostate cancer imaging and treatment
18 Jul 2023

 

 Owen Roberts

  • CEO, The Centre for Probe Development and Commercialization (CPDC)

Neil Vasdev, Ph.D., ACSF, FRSC (UK), FSNMMI

  • Director and Chief Radiochemist, The Centre for Addiction and Mental Health (CAMH)
 Using PET imaging in an open science model for a rare childhood brain cancer
19 Sep 2023 Lisa Bodei, MD, PhD

  • Attending Physician, Director of Targeted Radionuclide Therapy, Molecular Imaging and Therapy, Memorial Sloan Kettering Cancer Centre (MSKCC)
 Predicting Response in Molecular Therapeutics
17 Oct 2023 Simone Pickel, PhD

  • Senior Clinical Research Manager, Pentixapharm AG

Neydher Berroterán-Infante, PhD

  • CMC Director, Pentixapharm AG
 CXCR4: The future of theranostics is now!
12 Dec 2023

 

 Leila Safavi, PhD

  • Ambassador at Oncidium Foundation,
  • Chief Scientific Officer at Bone-Rad Therapeutics and CEO of Purist Inc.
 Part 1: An overview of the Oncidium Foundation and it’s projects.

Part 2: Promising molecules and Radioisotopes in Nuclear Medicine.

 
16 Jan 2024

 

 Mary Jessel, PhD, MBA

  • SVP Global Medical Affairs, Telix Pharmaceuticals

Darren Patti, Pharm. D.

  • Chief Operating Officer, Americas, Telix Pharmaceuticals
 Future of Theranostics: Intersection of precision medicine, innovation, and execution
17 Sep 2024

 

 BRUCE POWER SEED GRANT RECIPIENT

Zaynab Muraj

  • Radiation Therapist, RMP, UHN

Michael Valic

  • PhD Student, UHN
 Patient-Focused Radiotheranostics: Understanding Clinical Pathways for Better Care

 

Preclinical development of targeted Copper-64/Copper-67 theranostic nanotechnologies for the management of peritoneal carcinomatosis
29 Oct 2025

 

 Marian Meckel, PhD

  • Vice President Research and Development, ITM Medical Isotopes
 ITMs holistic Approach to Nuclear Medicine
14 Jan 2025

 

 Jason Van Wart, MSc, MBA 

  • President and CEO, Laurentis Energy Partners
 Laurentis Energy Partners: Leading the charge to meet global isotope demand.
4 Feb 2025

 

 James Scongack

  • Chief Operating Officer & Executive Vice-President, Bruce Power
 Isotopes for Hope
11 Mar 2025

 

 Vineet Prakash, MD

  • Royal Surrey Cancer Centre, NHS
 UK Hospital Experience in Healthcare System Readiness for Radiopharmaceuticals
22 Apr 2025

 

 Daniel Zikovitz, PhD

  • Director of Digital Innovation & AI, GE Healthcare

Ilya Gipp, MD, PhD

  • Chief Medical Officer – Oncology, GE Healthcare
 Reducing Uncertainties in Outcomes of Radioligand Therapy Through Harnessing

 

Data‑Driven Insights
5 Aug 2025

 

 Melissa Chassé, PhD candidate

  • Vasdev Lab, CAMH & UofT
 Radioligand Research and Development in Neuro‑Oncology
16 Sep 2025

 

 Fernando Frankel, PhD

  • Clinical Research Medical Advisor, Novartis Canada
 Novartis Oncology Pipeline Updates
14 Oct 2025

 

 Mark Macsuka, PhD candidate

  • University of Oxford
 Towards Personalised 177Lu-DOTATATE Therapy: Linking Dose and Response
10 Feb 2026

 

 Ben Pais, MD

  • Chief Medical Officer, NUCLIDIUM
 The novel theranostic pair Cu-61/67: unique production, manufacturing, and clinical advantages brought together in two new molecules for PET imaging and radioligand therapy
31 Mar 2026

 

 Munir Ghesani, MD, FACNM, FACR, FSNMMI

  • Chief Medical Officer & Medical Director, United Theranostics
 From Molecular Vision to Therapeutic Reality: The Past, Present, and Future of Theranostics
21 Apr 2026

 

 Joseph Osborne, MD, PhD

  • Chief of Molecular Imaging and Therapeutics,
  • Professor of Radiology at Weill Cornell Medicine,
  • Attending Radiologist at New York-Presbyterian/Weill Cornell Medicine
 Theranostics in practice: Focus on prostate cancer targeted nuclides

 

Need help? Book a call at a time to suit your schedule

Contact us to learn more about the program or if you'd like to set up a time to discuss further how you can help the program or how the program can help you.

Book a Call